

Emyria and Cann Group mutually agree to terminate collaboration arrangements



Emyria Limited (ASX: EMD) (Emyria) and **Cann Group** Limited (ASX: CAN) (Cann Group) today announced that both companies have mutually agreed to terminate a collaboration agreement relating to the planned registration of a Schedule 3 (S3) medicine CBD product.

The collaboration was announced via an ASX release on 29 March and envisaged that both companies would co-operate to progress a Schedule 3 over-the-counter cannabidiol (CBD) medicine with Australia's Therapeutic Goods Administration (TGA) by utilising Emyria's EMD-003 drug development program and Cann's proprietary Gelpell microsphere technology.

Following a detailed review, both companies have agreed to formally terminate those arrangements and mutually release each other from the obligations of the collaboration agreement.

Both Emyria and Cann plan to independently pursue registration programs for an S3 CBD product.

This announcement has been approved and authorised for release by the Board of Emyria Limited and the Board of Cann Group Limited.

For all enquiries to Emyria please contact:

Dr. Michael Winlo
Managing Director
1300 436 363
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

Andrew Williams
Media Relations
+61 (0) 412 614 125
andreww@profilemedia.com.au

For all media enquiries to Cann please contact

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com



About Emyria (www.emyria.com)

Emyria Limited is a clinical drug development and care delivery company. **Emyria's Treatments** target large unmet needs and are focused on obtaining approval ("registration") with major global regulators. Emyria's treatment development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. The company has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation facility near Mildura, Victoria. Cann Group has executed collaboration agreements that have enabled it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products. Learn more about Cann Group at www.canngrouponlimited.com

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.